Achondrogenesis Market size was estimated at over USD 2.2 billion in 2024 and is poised to reach USD 3.9 billion by the end of 2037, expanding at a CAGR of 5% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of achondrogenesis is evaluated at USD 2.3 billion.
Increasing awareness about early diagnosis and informed decision-making in cases of complicated pregnancies are the major growth factors in the market. As more people seek advanced diagnostic methods for pre-hand information about the fetus containing rare genetic diseases, demand in this sector rises. Thus, increasing incidences of rare genetic disorders are influencing healthcare organizations and soon-to-be parents to incorporate these diagnostic procedures into prenatal screening routines. According to a report published by NLM, in October 2022, around 6,000–8,000 unique rare diseases (RDs) were detected globally, 80% of which originated from genetic malformations. The report further highlighted 50–75% of the cases being pediatric onset.
Further, the rising prevalence is attracting pharmaceutical companies and laboratories to invest in the achondrogenesis market, solidifying their grip on the global preventive and diagnostic industry. On this note, the expansion of this industry is fueling the genetic testing businesses, creating large consumer bases for this sector. According to a Research Nester report, the global genetic testing trade value is expected to reach USD 72.0 billion by the end of 2037. Its size is also projected to garner a value of USD 24.4 billion in 2025. The enlarging marketplace is further creating business opportunities for the global players in this sector, inspiring them to introduce more innovative diagnostic solutions to control the growing population of patients with hereditary illnesses worldwide.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5% |
|
Base Year Market Size (2024) |
USD 2.2 billion |
|
Forecast Year Market Size (2037) |
USD 3.9 billion |
|
Regional Scope |
|
Type (Type IA, Type IB, Type II)
Based on type, the type IA segment is set to capture over 48.3% achondrogenesis market share by 2037. Extensive research on the underlying genetic mutation of this rare disorder, having a considerably higher prevalence rate is propelling investment in this segment. The growing involvement of well-known research institutes in such studies to introduce potential faulty gene correcting or mitigating methods is also inspiring others to invest in this sector. For instance, in June 2022, a study paper was released by the ISUOG, discussing the classifications and possible symptom management solutions. The statistics revealed a significantly higher chance of 25% of having pregnancies affected with type IA and type IB achondrogenesis after one’s first incidence.
Diagnosis (Physical Examination, Molecular Genetic Testing, Biochemical Testing)
In terms of diagnosis, the molecular genetic testing segment is anticipated to capture a significant share of the achondrogenesis market by the end of 2037. The diverse range of end users of this advanced diagnostic technique is the major driving factor in this segment. As genomic technology develops, innovation in associative testing methods becomes more frequent, marking progress in this segment. According to a report published by the American Society of Human Genetics (ASHG), in May 2021, the human genetics and genomics domain in the U.S. generated USD 5.2 billion in direct operations. The report further states, that this category surpassed all federal agencies by securing the single-year federal investment of USD 3.3 billion in the same year.
Our in-depth analysis of the global achondrogenesis market includes the following segments:
|
Type |
|
|
Diagnosis |
|
|
End user |
|
North America Market Analysis
North America in achondrogenesis market is poised to hold more than 45.7% revenue share by 2037. The region’s healthcare infrastructure is enforced with advanced diagnostic tools such as genetic testing and imaging systems, which ignites demand in this sector. In addition, it has become one of the founding stones of R&D in this market due to being highly specialized in pediatric care and genomics. According to a Research Nester report, the human genomics industry of North America is estimated to hold the largest share of 45% by 2037, surged by the heavy usage of genetic expressions in drug discoveries and accelerated R&D in pharmaceuticals.
The U.S. is placing itself at the forefront of the regional achondrogenesis market by generating significant revenues from the human genetics industry. Additionally, with the supportive framework of the federal government, this country is auguring in garnering great opportunities for domestic and international leaders in this sector. According to an ASHG report, published in May 2021, the human genetics and genomics industry of the U.S. contributed to the national economy with around USD 265 billion in 2019.
Canada is investing significantly in the achondrogenesis market as a part of its strategy to make RD medication and therapeutics such as orphan drugs more accessible and effective through R&D. The country is focusing on offering all aspects of healthcare to the future generation by developing new solutions. For instance, in February 2024, the government of Canada announced a funding of USD 20 million over five years to build the Pediatric Rare Disease Clinical Trials and Treatment Network (RareKids-CAN).
APAC Market Statistics
APAC is poised to register the fastest growth in the achondrogenesis market due to its wide range of applications in clinical research activities. The engaged organizations tend to invest in advanced diagnostic tools for developing better management and therapeutic interventions for genetically ill patients and high-risk pregnancies. For instance, in June 2021, Illumina partnered with Next Generation Genomic Co., Ltd. for the commercial launch of the CE-IVD VeriSeq NIPT Solution v2 in Thailand. After receiving approval from the regulatory body in November 2020, the company aimed to roll out its non-invasive testing method across Southeast Asia by offering valuable health insights during pregnancy.
The achondrogenesis market in India is gaining traction due to the growing awareness about the benefits of prenatal tests, inspiring global leaders to acquire the country’s wide marketplace. Thus, the growing investments in the domestic medical diagnostic industry are inflating demand in this sector. According to a report published by the International Trade Administration, in April 2023, the industry of POCT diagnostic products including molecular testing in India is estimated to reach USD 70 million by 2030.
China is aimed at revolutionizing the achondrogenesis market by introducing advanced testing solutions through biotechnology. For instance, in February 2024, a study report on new advances from the China Neonatal Genomes Project (CNGP) was published. The report highlighted the usage of genome data from 100,000 cases under this project in developing next-generation sequencing technologies to enhance patient outcomes. Evaluation of these genotype-phenotype correlations in neonatal rare diseases further revealed utility in precision medicine.
The dynamics of this market are evolving with the integration of advanced technologies such as AI and cloud computing. The biotech leaders are utilizing it as a golden opportunity to leverage their progress in this field. They are also engaging in strategic collaborations & investments and product launches to solidify their position, expanding their footprint across the globe. For instance, in March 2024, Igentify launched Non-Invasive Prenatal Testing (NIPT) and Pharmacogenomics (PGx) offerings through a Digital Genetic Assistant platform. The launch was made to expand its portfolio by streamlining research and clinical workflow with better genetic data management. Such key players include:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?